{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:10:53Z","timestamp":1785510653577,"version":"3.56.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106152","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:01:35Z","timestamp":1781136095000},"page":"106152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Generic parenteral products: Regulatory, safety, and toxicological facets"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4086-2452","authenticated-orcid":false,"given":"Pradip","family":"Karale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eram","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwal","family":"Havelikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raosaheb","family":"Shendage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106152_bib1","doi-asserted-by":"crossref","DOI":"10.53555\/AJBR.v28i2S.6372","article-title":"Evolution and convergence of vaccine regulatory systems: a tri-country analysis of India, Australia, and Japan","author":"Aa","year":"2025","journal-title":"Afr. J. Biomed. Res."},{"key":"10.1016\/j.yrtph.2026.106152_bib2","series-title":"Handbook of Validation in Pharmaceutical Processes [Internet]","first-page":"457","article-title":"Manual aseptic processes","author":"Agalloco","year":"2021"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.apsb.2018.07.011","article-title":"Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications","volume":"8","author":"Ahire","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.yrtph.2026.106152_bib4","series-title":"Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology [Internet]","first-page":"335","article-title":"Sterile dosage forms loaded nanosystems for parenteral, nasal, pulmonary and ocular administration","author":"Ahmed","year":"2018"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/cpt.3133","article-title":"Challenging the norm: a multidisciplinary perspective on intravenous to subcutaneous bridging strategies for biologics","volume":"115","author":"Ait\u2010Oudhia","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106152_bib6","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/jps.10154","article-title":"Excipient\u2013drug interactions in parenteral formulations","volume":"91","author":"Akers","year":"2002","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib7","first-page":"33","article-title":"Brand and generic medications: are they interchangeable?","volume":"28","author":"Al-Jazairi","year":"2008","journal-title":"Ann. Saudi Med."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106152_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s42452-025-07712-9","article-title":"Continuous pharmaceutical manufacturing and its contemporary regulatory insights","volume":"7","author":"Alemie","year":"2025","journal-title":"Discov. Appl. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib9","series-title":"The Art, Science, and Technology of Pharmaceutical Compounding","author":"Allen","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106152_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.yrtph.2018.12.007","article-title":"Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses","volume":"102","author":"Amberg","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17764\/1557-2196-64.1.1","article-title":"Strategies for the control of visible particles in Sterile devices","volume":"64","author":"Ashtekar","year":"2021","journal-title":"J. IEST"},{"key":"10.1016\/j.yrtph.2026.106152_bib175","series-title":"Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging\/Delivery Systems","year":"1664"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.33545\/26646862.2025.v7.i1e.136","article-title":"Advancements in parenteral preparation techniques: a review article","volume":"7","author":"Badhan","year":"2025","journal-title":"Int. J. Pharmaceut. Res. Dev."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/ejhpharm-2024-004340","article-title":"Exposure to potentially harmful excipients in neonates admitted to intensive care units using compounded medicines","volume":"33","author":"Barbosa","year":"2026","journal-title":"Eur. J. Hosp. Pharm. Sci. Pract."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2006.10.010","article-title":"Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications","volume":"59","author":"Basak","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.yrtph.2026.106152_bib15","series-title":"Principles of Parenteral Solution Validation [Internet]","first-page":"33","article-title":"Aseptic process validation: aseptic process simulation design","author":"Baseman","year":"2020"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106152_bib16","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s11095-022-03391-y","article-title":"Current state and opportunities with long-acting injectables: industry perspectives from the innovation and quality Consortium \u201cLong-Acting Injectables\u201d Working Group","volume":"40","author":"Bauer","year":"2023","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106152_bib17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/biomedicines10092055","article-title":"Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics","volume":"10","author":"Bhalani","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/17411343231194755","article-title":"Regulatory framework and disparities of complex generics in United States, European Union & Latin America","volume":"19","author":"Bhatt","year":"2023","journal-title":"J. Generic Med. Bus. J. Generic Med. Sect."},{"key":"10.1016\/j.yrtph.2026.106152_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119840","article-title":"Buclizine crystal forms: First structural determinations, counter-ion stoichiometry, hydration, and physicochemical properties of pharmaceutical relevance","volume":"589","author":"Bitencourt","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs\u2014A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.apsb.2013.07.004","article-title":"Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984","volume":"3","author":"Boehm","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib23","doi-asserted-by":"crossref","DOI":"10.1208\/ps060111","article-title":"Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report","volume":"6","author":"Burgess","year":"2004","journal-title":"AAPS PharmSci"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejps.2004.03.001","article-title":"Assuring quality and performance of sustained and controlled release parenterals","volume":"21","author":"Burgess","year":"2004","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124163","article-title":"Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration?","volume":"657","author":"Camacho Vieira","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106152_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.44670","article-title":"Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland","volume":"5","author":"Carl","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/pharmaceutics15041132","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates administered via subcutaneous and intratumoral routes","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yrtph.2026.106152_bib29","article-title":"Parenteral microemulsions for drug delivery: advances and update","volume":"89","author":"Chavda","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.yrtph.2026.106152_bib30","series-title":"Pharmaceutical Quality by Design [Internet]","first-page":"151","article-title":"QbD-Based development of pharmaceutical parenteral drug products: an overview","author":"Chobisa","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106152_bib31","author":"Choudhary"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wics.1310","article-title":"Bioavailability and bioequivalence in drug development","volume":"6","author":"Chow","year":"2014","journal-title":"Wiley Interdiscip. Rev. Comput. Stat."},{"key":"10.1016\/j.yrtph.2026.106152_bib33","series-title":"FDA [Internet]","article-title":"Search for FDA guidance documents","year":"2026"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1542\/peds.99.2.268","article-title":"\u201cInactive\u201d ingredients in pharmaceutical products: Update (Subject review)","volume":"99","year":"1997","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/antibiotics12050935","article-title":"Clinical equivalence between Generic versus branded antibiotics: systematic review and meta-analysis","volume":"12","author":"Cotia","year":"2023","journal-title":"Antibiotics"},{"issue":"10","key":"10.1016\/j.yrtph.2026.106152_bib36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1289\/ehp.1001931","article-title":"The future use of in vitro data in risk assessment to set human exposure standards: challenging problems and familiar solutions","volume":"118","author":"Crump","year":"2010","journal-title":"Environ. Health Perspect."},{"issue":"8\u20139","key":"10.1016\/j.yrtph.2026.106152_bib37","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.ces.2004.11.013","article-title":"More efficient preparation of parenteral emulsions or how to improve a pharmaceutical recipe by formulation engineering","volume":"60","author":"Cu\u00e9llar","year":"2005","journal-title":"Chem. Eng. Sci."},{"issue":"26","key":"10.1016\/j.yrtph.2026.106152_bib38","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1056\/NEJMc1711899","article-title":"Prices of generic drugs associated with numbers of manufacturers","volume":"377","author":"Dave","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib39","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","article-title":"International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences","volume":"15","author":"Davit","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.yrtph.2026.106152_bib40","article-title":"A comparative analysis of generic drug assessment and regulatory approval in the USA, Europe and India","year":"2024","journal-title":"Chin. J. Appl. Physiol."},{"key":"10.1016\/j.yrtph.2026.106152_bib41","unstructured":"Determining whether to submit an ANDA or a 505(b)(2) Application.."},{"key":"10.1016\/j.yrtph.2026.106152_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-14-1","article-title":"A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study","volume":"14","author":"Dunne","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.yrtph.2026.106152_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114791","article-title":"A holistic science-based approach to container closure integrity for parenteral products: lessons learned from a vaccine requiring deep cold storage using a conventional vial system","volume":"214","author":"Edey","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106152_bib45","article-title":"Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment","volume":"17","author":"More","year":"2019","journal-title":"EFSA J."},{"key":"10.1016\/j.yrtph.2026.106152_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/CEOR.S317687","article-title":"Payer perspectives on intravenous versus subcutaneous administration of drugs","volume":"13","author":"Epstein","year":"2021","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.yrtph.2026.106152_bib47","series-title":"Introduction to Quality by Design (Qbd) [Internet]","first-page":"217","article-title":"Quality by design for parenteral formulations","author":"Ergin","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106152_bib48","series-title":"EudraLex - Volume 4 - Public Health - European Commission [Internet]","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106152_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejpb.2023.04.002","article-title":"Stability and compatibility of parenteral nutrition solutions; a review of influencing factors","volume":"187","author":"Farhan","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s43441-019-00036-y","article-title":"Review of drugs approved via the 505(b)(2) pathway: uncovering drug development trends and regulatory requirements","volume":"54","author":"Freije","year":"2020","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpt.3659","article-title":"Frequency and nature of generic \u201cDesign Around\u201d of brand\u2010name patents in the United States","volume":"118","author":"Freilich","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5530\/ijper.53.3.74","article-title":"Manufacturing and control (CMC) evaluations of ANDA submission in the USA","volume":"53","author":"G","year":"2019","journal-title":"Indian J Pharm Educ Res"},{"key":"10.1016\/j.yrtph.2026.106152_bib55","series-title":"Pharmaceutical Preformulation and Formulation: a Practical Guide from Candidate Drug Selection to Commercial Dosage Form","author":"Gibson","year":"2009"},{"key":"10.1016\/j.yrtph.2026.106152_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.70604\/jmtbas.v2i1.52","article-title":"Regulatory affairs and regulatory requirements for new drug approval","volume":"25","author":"Gorle","year":"2025","journal-title":"J Mod Tech Biol Allied Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib57","year":"2004","journal-title":"Guidance for Industry"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/187221111795471391","article-title":"Parenteral drug delivery: a review","volume":"5","author":"Gulati","year":"2011","journal-title":"Recent Pat. Drug Deliv. Formulation"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/futurepharmacol5020018","article-title":"Scientifically supported best practices in leachable screening studies for pharmaceutical and parenteral drug products","volume":"5","author":"Gusain","year":"2025","journal-title":"Future Pharmacol"},{"key":"10.1016\/j.yrtph.2026.106152_bib61","series-title":"Ophthalmic Product Development [Internet]","first-page":"199","article-title":"Microbiological considerations for ophthalmic products: sterility, endotoxin limits, and preservatives","author":"Hasegawa","year":"2021"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/chromsci\/bmv248","article-title":"QbD-Driven development and validation of a bioanalytical LC-MS method for quantification of fluoxetine in human plasma","volume":"54","author":"Hasnain","year":"2016","journal-title":"J. Chromatogr. Sci."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106152_bib63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2131\/jts.50.471","article-title":"Estimation of intravenous TTC (TTCiv) for extractables and leachables (E&Ls) by applying a modifying factor based on blood concentration predicted using an open-source PBPK model","volume":"50","author":"Hayashi","year":"2025","journal-title":"J. Toxicol. Sci."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106152_bib64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMc1415471","article-title":"High-cost generic drugs \u2014 implications for patients and policymakers","volume":"372","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.18579\/jopcr\/v22.4.81","article-title":"Analytical QBD approach to redefine the quality of pharmaceuticals: a review","volume":"22","author":"Ameen","year":"2023","journal-title":"J. Pharm. Res."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/nyas.13347","article-title":"Equivalence of complex drug products: advances in and challenges for current regulatory frameworks","volume":"1407","author":"Hussaarts","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib68","series-title":"ICH Q3E Extractables and Leachables - Scientific Guideline | European Medicines Agency (EMA)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106152_bib71","series-title":"Inspection Observations","year":"2025"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/adt.2024.122","article-title":"Mini review on the lyophilization: a basic requirement for formulation development and stability modifier","volume":"23","author":"Joshi","year":"2025","journal-title":"Assay Drug Dev. Technol."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106152_bib73","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.xphs.2023.08.004","article-title":"Regulatory experience with continuous manufacturing and real time release testing for dissolution in new drug applications","volume":"112","author":"Kakhi","year":"2023","journal-title":"J. Pharmacol. Sci."},{"issue":"21","key":"10.1016\/j.yrtph.2026.106152_bib74","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/092986706778201648","article-title":"Drug excipients","volume":"13","author":"Kalasz","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.yrtph.2026.106152_bib75","article-title":"Artificial intelligence in pharmaceutical sciences: a comprehensive review","volume":"27","author":"Kandhare","year":"2025","journal-title":"Med Nov Technol Devices"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106152_bib76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-015-0382-1","article-title":"Modified regulatory pathways to approve generic drugs in the US and a systematic review of their outcomes","volume":"75","author":"Kesselheim","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib77","first-page":"122","article-title":"Quality by design- newer technique for pharmaceutical product development","volume":"2","author":"Khan","year":"2024","journal-title":"Int. Pharmacop."},{"key":"10.1016\/j.yrtph.2026.106152_bib78","series-title":"Specification of Drug Substances and Products [Internet]","first-page":"715","article-title":"General analytical considerations for parenteral products","author":"Kikovska-Stojanovska","year":"2025"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib79","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1007\/s11095-011-0385-x","article-title":"The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics","volume":"28","author":"Kishore","year":"2011","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.14662","article-title":"A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways","volume":"1502","author":"Klein","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106152_bib81","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1111\/cts.13670","article-title":"Global harmonization of immediate\u2010release solid oral drug product bioequivalence recommendations and the impact on generic drug development","volume":"16","author":"Kotsybar","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106152_bib83","article-title":"Application of lyophilization in pharmaceutical injectable formulations: an industry and regulatory perspective","volume":"100","author":"Kumar","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.22270\/ijdra.v12i2.676","article-title":"Overview and lifecycle management of generic pharmaceutical drugs in Mexico, Guatemala and Brazil","volume":"12","author":"Kuveria","year":"2024","journal-title":"Int J Drug Regul Aff"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/toxics14010092","article-title":"Extractables and leachables in pharmaceutical products: potential adverse effects and toxicological risk assessment","volume":"14","author":"Kuzmi\u010d","year":"2026","journal-title":"Toxics"},{"key":"10.1016\/j.yrtph.2026.106152_bib92","series-title":"The Politics of the Pharmaceutical Industry and Access to Medicines: World Pharmacy and India [Internet]","year":"2017"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib88","first-page":"277","article-title":"Propylene glycol toxicity in children","volume":"19","author":"Lim","year":"2014","journal-title":"J Pediatr Pharmacol Ther JPPT Off J PPAG"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12248-011-9312-7","article-title":"Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA","volume":"14","author":"Liu","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.yrtph.2026.106152_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2024.100175","article-title":"Visible particles in parenteral drug products: a review of current safety assessment practice","volume":"7","author":"Liu","year":"2024","journal-title":"Curr Res Toxicol"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib94","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1081\/DDC-120037484","article-title":"Characterization of Amphotericin B liposome formulations","volume":"30","author":"Manosroi","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8\u20139","key":"10.1016\/j.yrtph.2026.106152_bib95","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3109\/03639048409039056","article-title":"Stability of parenterals","volume":"10","author":"Mendenhall","year":"1984","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib96","doi-asserted-by":"crossref","first-page":"165","DOI":"10.33320\/maced.pharm.bull.2020.66.03.082","article-title":"Some challenges in global clinical development of generic products","volume":"66","author":"Mileva","year":"2020","journal-title":"Maced Pharm Bull"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106152_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/nrd4686","article-title":"Should the FDA disclose complete response letters?","volume":"14","author":"Mullard","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib98","doi-asserted-by":"crossref","first-page":"73","DOI":"10.22270\/ijdra.v13i2.764","article-title":"Artificial intelligence in regulatory compliance: transforming pharmaceutical and healthcare documentation","volume":"13","author":"Muppalla","year":"2025","journal-title":"Int J Drug Regul Aff"},{"key":"10.1016\/j.yrtph.2026.106152_bib99","series-title":"Continuous Pharmaceutical Processing and Process Analytical Technology","year":"2023"},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2026.106152_bib100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0163-7258(94)90004-3","article-title":"Bioequivalence requirements for generic products","volume":"62","author":"Nation","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2026.106152_bib101","series-title":"Comparison of regulatory requirements for generic drugs dossier in united states and europe [internet]","author":"Naveen Kumar MN","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106152_bib102","series-title":"Parenteral Medications","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106152_bib103","series-title":"Parenteral Medications","first-page":"1","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106152_bib104","series-title":"Parenteral Medications","first-page":"1","year":"2019"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib106","doi-asserted-by":"crossref","DOI":"10.1080\/20016689.2022.2147286","article-title":"Proposal of International Council for Harmonization (ICH) Guideline for the approval of biosimilars","volume":"11","author":"Niazi","year":"2023","journal-title":"J Mark Access Health Policy"},{"issue":"9","key":"10.1016\/j.yrtph.2026.106152_bib107","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/jps.24434","article-title":"Organic anion transporter 4-Mediated transport of Olmesartan at basal plasma membrane of human placental barrier","volume":"104","author":"Noguchi","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","article-title":"Challenges and opportunities in the development of complex generic long-acting injectable drug products","volume":"336","author":"O'Brien","year":"2021","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ajhp\/59.3.264","article-title":"Compliance with safe practices for preparing parenteral nutrition formulations","volume":"59","author":"O'Neal","year":"2002","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13346-022-01223-5","article-title":"An expanding horizon of complex injectable products: development and regulatory considerations","volume":"13","author":"Panchal","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.yrtph.2026.106152_bib111","series-title":"Delivery of Drugs [Internet]","first-page":"191","article-title":"Complex injectables","author":"Pandey","year":"2020"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s43094-023-00551-8","article-title":"Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review","volume":"9","author":"Pardeshi","year":"2023","journal-title":"Future J. Pharmaceut. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105776","article-title":"Comprehensive extractables and leachables sensitization analysis and practical application of a risk-based approach to sensitization assessment for parenteral drug products","volume":"157","author":"Parris","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106152_bib114","unstructured":"Particulate Contamination | USP [Internet]. [cited 2026 Apr 8]. Available from: https:\/\/www.usp.org\/harmonization-standards\/pdg\/general-methods\/particulate-contamination."},{"issue":"21","key":"10.1016\/j.yrtph.2026.106152_bib115","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.3390\/ijms21218224","article-title":"Pharmaceutical excipients and drug metabolism: a mini-review","volume":"21","author":"Patel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.56782\/pps.245","article-title":"Current trends in manufacturing for large volume parenteral in the pharmaceutical industry and future scopes","volume":"23","author":"Patel","year":"2025","journal-title":"Prospects Pharm Sci"},{"key":"10.1016\/j.yrtph.2026.106152_bib117","doi-asserted-by":"crossref","DOI":"10.2174\/012210299X269535231203164108","article-title":"Current regulatory framework and challenges for the approval of ComplexGenerics in the US and the EU","volume":"2","author":"Patil","year":"2024","journal-title":"Curr Indian Sci"},{"key":"10.1016\/j.yrtph.2026.106152_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharma.2025.03.001","article-title":"Regulatory frameworks and filing discrepancies in generic drug approvals: a cross-regional study with analysis of FDA ANDA deficiencies","author":"Pawar","year":"2025","journal-title":"Ann. Pharm. Fr."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib119","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s43441-025-00755-5","article-title":"Focusing on first cycle approval in ANDA submission: understanding common deficiencies & case study insights","volume":"59","author":"Pawar","year":"2025","journal-title":"Ther Innov Regul Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2012.10.006","article-title":"An introduction to the Most cited papers in the history of Advanced Drug Delivery Reviews (1987\u20132012)","volume":"64","author":"Peppas","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.yrtph.2026.106152_bib121","series-title":"Pharmaceutical Dosage Forms - Parenteral Medications: Volume 3: Regulations, Validation and the Future","year":"2010"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106152_bib122","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/10837450.2019.1585449","article-title":"The need for new control strategies for particulate matter in parenterals","volume":"24","author":"Poms","year":"2019","journal-title":"Pharmaceut. Dev. Technol."},{"key":"10.1016\/j.yrtph.2026.106152_bib123","unstructured":"Product Quality Research Institute \u2013 Product quality research institute [Internet]. [cited 2026 Apr 8]. Available from: https:\/\/pqri.org\/."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106152_bib124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4236\/ajac.2024.1512025","article-title":"Strengthening extractable & leachable study submissions: best practices to avoid regulatory deficiencies","volume":"15","author":"Ramamoorthy","year":"2024","journal-title":"Am. J. Anal. Chem."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib125","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5731\/pdajpst.2020.011734","article-title":"Industry one-voice-of-quality (1VQ) solutions: effective management of post-approval changes in the pharmaceutical quality system (PQS)\u2014Through enhanced science and risk-based approaches","volume":"74","author":"Ramnarine","year":"2020","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1208\/s12249-025-03087-7","article-title":"Development of complex generics and similar biological products: an industrial perspective of reverse engineering","volume":"26","author":"Ranjan","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.26452\/ijebr.v3i3.635","article-title":"Recent approaches of regulatory perspectives for the registration of drugs in southern states in India","volume":"3","author":"Rathapani","year":"2024","journal-title":"Int J Exp Biomed Res"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.addr.2003.10.011","article-title":"Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs)","volume":"56","author":"Raw","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106152_bib129","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/03639045.2018.1483392","article-title":"Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics","volume":"44","author":"Rayaprolu","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.yrtph.2026.106152_bib130","series-title":"Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products [Internet]","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106152_bib133","series-title":"Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry [Internet]","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106152_bib139","series-title":"Pyrogen and Endotoxins Testing: Questions and Answers [Internet]","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106152_bib131","series-title":"ANDA Submissions -- refuse-to-receive Standards Rev.2 [Internet]","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106152_bib134","series-title":"Q9(R1) Quality Risk Management [Internet]","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106152_bib132","series-title":"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients [Internet]","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106152_bib135","series-title":"Sterile Drug Products Produced by Aseptic Processing \u2014 Current Good Manufacturing Practice [Internet]","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106152_bib138","series-title":"Q1 Stability Testing of Drug Substances and Drug Products [Internet]","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106152_bib136","series-title":"Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [Internet]","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106152_bib140","article-title":"Fda","year":"2025","journal-title":"Turbare Manufacturing"},{"key":"10.1016\/j.yrtph.2026.106152_bib141","series-title":"Stability Testing of New Drug Substances and Products [Internet]","year":"2020"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib142","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/1475-6773.14145","article-title":"Market dynamics of authorized generics in medicaid from 2014 to 2020","volume":"58","author":"Rome","year":"2023","journal-title":"Health Serv. Res."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib143","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/pharmaceutics13030387","article-title":"Excipients in the paediatric population: a review","volume":"13","author":"Rouaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yrtph.2026.106152_bib144","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2023.04.010","article-title":"A review of paediatric injectable drug delivery to inform the study of product acceptability \u2013 an introduction","volume":"188","author":"Ruiz","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.yrtph.2026.106152_bib145","series-title":"Dosage Forms, Formulation Developments and Regulations [Internet]","first-page":"663","article-title":"Pharmaceutical packaging: recent trends and challenges","author":"Sah","year":"2024"},{"issue":"4-A","key":"10.1016\/j.yrtph.2026.106152_bib146","doi-asserted-by":"crossref","first-page":"803","DOI":"10.22270\/jddt.v9i4-A.3617","article-title":"Parenteral suspensions: stability enhancing liquid dosage forms","volume":"9","author":"Santosh Kumar","year":"2019","journal-title":"J. Drug Deliv. Therapeut."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib148","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.drudis.2019.12.008","article-title":"Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies","volume":"25","author":"Selmin","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib149","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14227\/DT220415P16","article-title":"Performance test for parenteral dosage forms","volume":"22","author":"Shah","year":"2015","journal-title":"Dissolution Technol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/17411343251313962","article-title":"Development of complex generics: insights into trends, challenges, and market opportunities","volume":"21","author":"Shaikh","year":"2025","journal-title":"J. Generic Med. Bus. J. Generic Med. Sect."},{"key":"10.1016\/j.yrtph.2026.106152_bib151","author":"Sharma"},{"key":"10.1016\/j.yrtph.2026.106152_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2023.114174","article-title":"Question-based review for pharmaceutical development: an enhanced quality approach","volume":"195","author":"Sim\u00f5es","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.yrtph.2026.106152_bib153","series-title":"Sterile Product Development [Internet]","first-page":"359","article-title":"Particulate matter in Sterile parenteral products","author":"Singh","year":"2013"},{"issue":"17","key":"10.1016\/j.yrtph.2026.106152_bib154","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1213978","article-title":"Fungal infections associated with contaminated methylprednisolone injections","volume":"369","author":"Smith","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106152_bib155","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2020.1805431","article-title":"Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates","volume":"19","author":"Sridharan","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.yrtph.2026.106152_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106173","article-title":"Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections","volume":"173","author":"Tadini","year":"2022","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib158","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/B:PHAM.0000016234.73023.75","article-title":"Design of freeze-drying processes for pharmaceuticals: practical advice","volume":"21","author":"Tang","year":"2004","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106152_bib159","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40268-023-00412-y","article-title":"A nontrivial analysis of patient safety risk from parenteral Drug- and medical device-borne endotoxin","volume":"23","author":"Tidswell","year":"2023","journal-title":"Drugs R&D"},{"issue":"3","key":"10.1016\/j.yrtph.2026.106152_bib160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5731\/pdajpst.2020.012526","article-title":"Sterility assurance\u2014current and future state","volume":"76","author":"Tidswell","year":"2022","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106152_bib161","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/2168479014553033","article-title":"Challenges in the Development of Drug\/Device and Biologic\/Device Combination Products in the United States and European Union: a summary from the 2013 DIA meeting on combination products","volume":"49","author":"Tsourounis","year":"2015","journal-title":"Ther Innov Regul Sci."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106152_bib162","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.xphs.2020.08.020","article-title":"The introduction of a new flexible in vivo predictive dissolution apparatus, GIS-Alpha (GIS-\u03b1), to study dissolution profiles of BCS class IIb drugs, dipyridamole and Ketoconazole","volume":"109","author":"Tsume","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.yrtph.2026.106152_bib164","unstructured":"Using the Inactive Ingredient Database Guidance for Industry."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0092861512443748","article-title":"Hybrid or mixed marketing authorization application in the European Union: not a trivial decision in new development programs for established drugs","volume":"46","author":"Vogel","year":"2012","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.yrtph.2026.106152_bib166","article-title":"Oxidation of polysorbates - an underestimated degradation pathway?","volume":"6","author":"Weber","year":"2023","journal-title":"Int. J. Pharm. X"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106152_bib167","first-page":"856","article-title":"Understanding the scientific issues embedded in the generic drug approval process","volume":"41","author":"Welage","year":"1996","journal-title":"J. Am. Pharmaceut. Assoc."},{"key":"10.1016\/j.yrtph.2026.106152_bib168","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejpb.2023.11.010","article-title":"Industry perspective on a holistic container closure integrity approach to parenteral combination products","volume":"194","author":"Wuchner","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106152_bib170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/pharmaceutics17050623","article-title":"Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106152_bib171","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.yrtph.2026.106152_bib172","article-title":"A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: a systematic review","volume":"70","author":"Zagalo","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.yrtph.2026.106152_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2022.07.014","article-title":"Quality by design (QbD) approach in marketing authorization procedures of non-biological complex drugs: a critical evaluation","volume":"178","author":"Zagalo","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.yrtph.2026.106152_bib174","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","volume":"923","author":"Zhou","year":"2015","journal-title":"Patient Prefer. Adherence"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323002600125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:36:25Z","timestamp":1785508585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323002600125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":156,"alternative-id":["S027323002600125X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106152","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generic parenteral products: Regulatory, safety, and toxicological facets","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106152"}}